Pharma & Medical ...
Follow
Find
18.1K views | +8 today
Pharma & Medical Devices
Latest news on patients, healthcare and medical devices from around the Web
Curated by Richard Meyer
Your new post is loading...
Your new post is loading...
Scooped by Richard Meyer
Scoop.it!

Why The FDA's Approval of Sandoz's Filgrastim (Zarzio) Is Good News For Patients

Why The FDA's Approval of Sandoz's Filgrastim (Zarzio) Is Good News For Patients | Pharma & Medical Devices | Scoop.it
The implications extend beyond cancer drugs. Biosimilars have the potential to significantly reduce the costs of modern health care for people with all kinds of illness
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

When medical apps do more harm than good

When medical apps do more harm than good | Pharma & Medical Devices | Scoop.it
Replacing clinic visits with smartphones can be a risky move. Here's why.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Why Yes, We Should Treat Cancer

Why Yes, We Should Treat Cancer | Pharma & Medical Devices | Scoop.it
To deny new cancer treatments that might prolong life in a good way, possibly for cure or a remission, or even just to tame the disease, is a misguided proposition.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Delivering Higher Value Care Means Spending More Time with Patients - HBR

Delivering Higher Value Care Means Spending More Time with Patients - HBR | Pharma & Medical Devices | Scoop.it
And it could lower costs in the long run.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Drug Prices, Generics and M&A Top the Agenda for 2015

Drug Prices, Generics and M&A Top the Agenda for 2015 | Pharma & Medical Devices | Scoop.it
A new year always brings new challenges, and the pharmaceutical industry certainly has its share.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Biogen Straps Fitbits Onto MS Patients' Wrists

Biogen Straps Fitbits Onto MS Patients' Wrists | Pharma & Medical Devices | Scoop.it
Data collected from the bands might lead to better treatments
Richard Meyer's insight:

Biogen’s Fitbit study, conducted with PatientsLikeMe, an online discussion platform for people with chronic diseases, tried to assess how likely patients would be to use the devices. Participants had to agree to share their data with PatientsLikeMe, which then sent the data to Biogen for analysis.

more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

What the Insurance Industry Can Do to Fix Health Care - HBR

What the Insurance Industry Can Do to Fix Health Care - HBR | Pharma & Medical Devices | Scoop.it
Use its market power for good.
Richard Meyer's insight:

Act as true partners to value-based providers. Most payers today are piloting new economic models that pay providers not for the services they provide but for the value they create. Most, however, are neglecting a key opportunity: helping providers change their operating model. To succeed in value-based care, providers need data, analytics, smart clinical-care teams, and managerial support. Insurers are well-positioned to provide all this. They can also help providers become more efficient and assist them in navigating the tricky financial transition from fee-for-service to fee-for-value economics. Most important, insurers can help the very best provider organizations succeed by using them as the core of attractive, competitively priced insurance products.

more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

41 percent of caregivers use some digital health device to provide care

41 percent of caregivers use some digital health device to provide care | Pharma & Medical Devices | Scoop.it
A report on digital health found that 40 percent of caregivers use some form of digital health device as a caregiving aid.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

FDA Oversight in the Internet Age

FDA Oversight in the Internet Age | Pharma & Medical Devices | Scoop.it
An FDA rebuke of televised comments made by Aegerion’s CEO—which led the company to air a TV commercial correcting the statements—was prompted by complaints from a government drug reviewer, according to emails viewed by The Wall Street Journal.
more...
Pharma Guy's curator insight, December 22, 2014 8:35 AM


This was clearly an effort by a CEO to boost his company's share price and his personal profits, which undoubtedly depend on the price of the shares.


The Wall Street Journal Article also reveals that Mr. Beer, who became Aegerion’s CEO in 2010, "oversaw the company’s initial public offering and regulatory approval of Juxtapid, its first marketed drug. The Cambridge, Mass.-based company has 268 employees. Last year, Aegerion’s stock nearly tripled from $26.44 to $69.53 after Juxtapid sales got off to a strong start. However, a number of regulatory and legal problems, combined with disappointing Juxtapid sales, have caused the company’s share price to tumble nearly 69% to $22.81 since the beginning of 2014.


"Aegerion twice cut its sales guidance this year after it said more patients than expected quit taking Juxtapid because of the drug’s side effects, which include diarrhea, nausea and the risk of liver damage. Sales have also been hurt by an investigation by Brazilian authorities into whether Aegerion employees violated the country’s anticorruption laws in connection with the prescribing of Juxtapid there, the second-largest market for the drug after the U.S. The company said it doesn’t believe Brazil’s anticorruption laws have been broken.


The drug maker disclosed in January it is the subject of a U.S. Justice Department investigation into its sales and marketing of Juxtapid. The company said it is cooperating with the continuing investigation, and that it intends to vigorously defend itself."


Find the FDA letter here.

Claire Gorman's curator insight, January 15, 11:47 AM

We agree that there should be more accountability for what people publish on the Internet. There was not enough information provided to find anything to disagree with.

Scooped by Richard Meyer
Scoop.it!

Survey: Consumers want to be engaged by providers with patient portals

Survey: Consumers want to be engaged by providers with patient portals | Pharma & Medical Devices | Scoop.it
Consumers show a strong preference to getting their medical records online, if given instruction on how to easily access them, according to a survey by Xerox and Harris Poll
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Immuno-Oncology: Scratching The Surface

Immuno-Oncology: Scratching The Surface | Pharma & Medical Devices | Scoop.it
Another day, another announcement about great data from immuno-oncology.  It’s clearly one of the hottest fields in biopharma today, and has been for a few years.  The opening paragraph of a recent Leerink report by Seamus Fernandez and team on I/O is a great summary of the field today: [...]
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Biosimilar Drugs Face U.S. Test

Biosimilar Drugs Face U.S. Test | Pharma & Medical Devices | Scoop.it
The introduction in the U.S. of cheaper alternatives to complex biologic drugs faces a key test this week as an FDA panel decides whether to recommend approval of a ‘biosimilar’ drug.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

The True Cost Of Low Drug Prices

The True Cost Of Low Drug Prices | Pharma & Medical Devices | Scoop.it
India is not, yet, a wealthy country. Nevertheless its people experience many of the same expensive-to-treat illnesses as wealthier populations in the U.S. and Europe. Therefore the country has made a series of policy decisions designed to lower the cost of medical treatments. For example, until 2005, it offered no [...]
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Medicine Is About to Get Personal

How can Americans get better health care for less money? There's a quiet experiment going on among primary-care physicians, and the results are intriguing
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Grading Pharma In 2014: 17 Drug Companies Ranked

Grading Pharma In 2014: 17 Drug Companies Ranked | Pharma & Medical Devices | Scoop.it
Last year I gave grades to 16 large-cap pharmaceutical companies. It only seemed right to do it again.  I've given letter grades between F and A+ to all pharmaceutical companies that have market capitalizations above $50 billion (now there are 17, one more than last year). It's like high school with unpronounceable [...]
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Will 2015 deliver the promise of telemedicine?

Will 2015 deliver the promise of telemedicine? | Pharma & Medical Devices | Scoop.it
Telemedicine could very well explode in 2015, but only if the industry gets these 3 things right.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

People Are Shopping for Health Insurance, Surprisingly

People Are Shopping for Health Insurance, Surprisingly | Pharma & Medical Devices | Scoop.it
The high rate of shopping may be a good sign for the future of the exchanges, where price competition is the primary mechanism for keeping premiums low.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Patients Turn to Palliative Care for Relief from Serious Illness

Patients Turn to Palliative Care for Relief from Serious Illness | Pharma & Medical Devices | Scoop.it
Patients struggling with serious diseases and conditions are increasingly turning to palliative-care specialists for more day to day help with pain medication, treatment side effects as well as stress management.
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

What Your Doctor Worries About: Ethics Survey 2014

What Your Doctor Worries About: Ethics Survey 2014 | Pharma & Medical Devices | Scoop.it
Patients who smoke, refuse to diet, or are otherwise unwilling to participate in their own care should be forced to pay more because they represent a greater burden on the medical system, according to 69% of survey respondents.
Richard Meyer's insight:

Patients who smoke, refuse to diet, or are otherwise unwilling to participate in their own care should be forced to pay more because they represent a greater burden on the medical system, according to 69% of survey respondents.

more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

FDA approves Bristol-Myers' immunotherapy for skin cancer

FDA approves Bristol-Myers' immunotherapy for skin cancer | Pharma & Medical Devices | Scoop.it
(Reuters) - The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date.Opdivo, or nivolumab, belongs to a promising
more...
No comment yet.
Scooped by Richard Meyer
Scoop.it!

Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited

Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited | Pharma & Medical Devices | Scoop.it
Insurers are hoping that a new competitor to Gilead Sciences’ drugs for the disease will drive down prices, though the new drug’s price is higher than was hoped.
more...
No comment yet.